RARE DISEASE
Alport syndrome
Alport syndrome
Alport syndrome
Synonyms: Alport deafness-nephropathy, Alport hearing loss-nephropathy
Synonyms: Alport deafness-nephropathy, Alport hearing loss-nephropathy
Synonyms: Alport deafness-nephropathy, Alport hearing loss-nephropathy
Drug discovery
14
drugs
With orphan designations
Overview
Alport syndrome is a rare genetic disorder caused by mutations in COL4A3-5 genes, disrupting type IV collagen production. This leads to progressive glomerular basement membrane damage, resulting in hematuria, proteinuria, and eventual kidney failure. Extrarenal manifestations include sensorineural hearing loss (30–50%) and ocular abnormalities (e.g., anterior lenticonus). X-linked inheritance accounts for 80–85% of cases. Treatment focuses on RAAS blockade (ACE inhibitors/ARBs) to slow kidney disease progression, with dialysis or transplant required for end-stage renal disease [1][2][12].
Population
Prevalence: ~1 in 50,000 live births worldwide [4][16]; affects ~30,000–60,000 individuals in the U.S. [2][19].
Inheritance: X-linked (80–85%), autosomal recessive (15%), or dominant (rare) [12][16].
Severity: Males with X-linked form often develop ESRD by age 40; females typically have milder symptoms [12][16].
Burden
Clinical: ESRD in >90% of untreated X-linked males by mid-adulthood; hearing loss in 30–50%, ocular defects in ~30% [2][12][16].
Economic: Lifetime costs of dialysis/transplant; off-label drug use increases financial strain [3][5].
Psychosocial: Impacts quality of life due to multisystem involvement and hereditary transmission risks [5][18].
Therapies
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare renal diseases, rare transplant-related disorders
Research Papers
590 drug discovery papers about Alport syndrome, with 5 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
590 drug discovery papers about Alport syndrome, with 5 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-02 | Patient-derived human induced pluripotent stem cell podocytes uncover endoplasmic reticulum and oxidative stress-mediated dysfunction in X-linked Alport syndrome.
X-linked Alport syndrome (XLAS) is an inherited nephropathy caused by pathogenic COL4A5 variants that lead to podocyte dysfunction and progressive kidney failure. However, the involvement of endoplasmic reticulum (ER) stress and oxidative stress in the development of XLAS remains insufficiently understood. This study aims to elucidate the contribution of ER and oxidative stress to podocyte injury in XLAS employing a patient-derived human induced pluripotent stem cell (hiPSC)-based podocyte model. Induced pluripotent stem cells were derived from XLAS patient blood cells and differentiated into podocytes (XLAS podocyte). Expression of pluripotency, lineage-specific, and podocyte markers was confirmed. ER stress, oxidative stress, and mitochondrial morphology were assessed through molecular characterization, imaging, and functional assays, comparing XLAS podocytes to wild-type (WT) hiPSC-derived podocytes. XLAS patient-derived hiPSCs maintained typical pluripotency markers, exhibited normal karyotypes, and allowed for successful tri-lineage differentiation. Relative to WT podocytes, XLAS podocytes had diminished expression of NPHS1, WT1, and COL4A5, while COL4A1 was increased. ER stress marker expression was elevated, with lower levels of CANX and CALR, indicative of unfolded protein response (UPR) activation. Electron microscopy analysis demonstrated enhanced ER enlargement in XLAS podocyte, implicating ER stress in disease pathogenesis. Moreover, XLAS podocytes showed markedly raised oxidative stress markers and mitochondrial reactive oxygen species (ROS) levels, together with altered catalase protein expression. Viability assays further supported ER and oxidative stress as contributors to reduced podocyte survival in XLAS podocyte. Our findings indicate that ER stress and oxidative stress are critical drivers of podocyte dysfunction in XLAS. UPR activation, ROS accrual, and mitochondrial impairment point to important therapeutic opportunities.
2026-06-19 | Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology.
Alport syndrome (AS) is a hereditary kidney disorder characterized by progressive hematuria, proteinuria, and kidney failure, frequently accompanied by hearing loss and ocular abnormalities. Although blockade of the renin-angiotensin system (RAS) is established as the first-line therapy, additional pharmacological interventions have been explored. To formulate evidence-based recommendations tailored to the Korean healthcare setting, the Genetic Kidney Disease Study Group of the Korean Society of Nephrology conducted a systematic review evaluating four therapeutic strategies: RAS blockade, cyclosporine, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation framework. The review confirmed that early initiation of RAS blockade delays progression to kidney failure and improves long-term survival, with the greatest benefit when initiated at the stage of microscopic hematuria or microalbuminuria. In contrast, evidence supporting cyclosporine , MRAs, and SGLT2i remains limited, primarily derived from small observational studies with short follow-up and heterogeneous populations. Although cyclosporine and MRAs have demonstrated short-term reductions in proteinuria, neither has shown sustained renoprotective effects, and cyclosporine is associated with a substantial risk of nephrotoxicity. Evidence regarding SGLT2i is inconsistent, with insufficient data on long-term efficacy in AS. Accordingly, these guidelines strongly recommend early RAS blockade as the cornerstone of AS, while no recommendations are made for routine use of cyclosporine, MRAs, or SGLT2i. Well-designed clinical trials are needed to expand therapeutic options and improve long-term outcomes in AS.
2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.
The global burden of chronic and genetic kidney diseases poses a significant challenge to healthcare systems. Current therapies, including dialysis, transplantation, and supportive pharmacotherapies, cannot halt disease progression or address root causes, especially in monogenic disorders like Alport syndrome and Fabry disease. Adeno-associated virus (AAV)-based gene therapy is promising, enabling targeted correction of underlying genetic defects. However, renal delivery faces challenges, including cellular heterogeneity, anatomical barriers, and pre-existing immunity. This review evaluates advances in AAV capsid engineering to overcome these obstacles, focusing on strategies to enhance kidney-specific tropism, transduction efficiency, and immune evasion. We outline the evolution from conventional serotype selection to precision engineering via rational design, directed evolution, and in silico approaches. Artificial intelligence (AI) has emerged as a pivotal accelerator, with machine learning models and generative frameworks enabling data-efficient capsid optimization despite limited datasets. Multimodal AI, reinforcement learning, and agentic systems can refine renal targeting by balancing glomerular penetration, cell specificity, and safety. Future progress relies on scaling high-quality datasets through collaborative consortia, lab-in-the-loop validation, and explainable AI. By combining capsid engineering with renal pathophysiology insights, this roadmap paves the way for curative AAV therapies that move beyond current suboptimal treatments to correct underlying pathogenic mechanisms.
2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.
Alport syndrome (AS) is an inherited disorder of the glomerular basement membrane (GBM) resulting from pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes, which encode the α3, α4, and α5 chains of type IV collagen, the main structural component of the GBM, cochlea, and lens capsule.Defects in this collagen network lead to progressive renal insufficiency, hearing impairment, and characteristic ocular lesions such as anterior lenticonus and retinal flecks.(1).AS affects approximately 1 in 50 000 live births.The disease is classically inherited in an X-linked pattern (85%), followed by autosomal recessive (15%) and autosomal dominant (< 1%) forms.The severity and age at onset vary depending on the mutation type and zygosity, with males with truncating COL4A5 variants typically progressing faster to end-stage kidney disease (ESKD).( 2 )
2026-05-15 | Albuminuria drives hyperlipidemia in patients with Alport syndrome.
Hypercholesterolemia is a major driver of cardiovascular disease, a leading cause of premature mortality in patients with chronic kidney disease (CKD). Despite their typically young age, patients with Alport syndrome (AS), the second most prevalent genetic cause of CKD, may face a disproportionately high risk of hypercholesterolemia. This study investigates whether increased albuminuria precipitates hyperlipidemia in this population to a degree comparable with general CKD cohorts, while further delineating the risk factors underlying this development. This was a multicenter, observational, non-interventional, and retrospective study. Among 459 patients with AS, 59.3% had hypercholesterolemia and 58.5% had elevated low-density lipoprotein cholesterol (LDL-C). Despite lower eGFR and higher albuminuria, patients with lipid-lowering therapy (LLT) had significantly lower total cholesterol levels compared to the untreated patients (193.6 ± 55.2 mg/dL vs. 208.2 ± 51.0 mg/dL; p = 0.044). Similarly, LDL-C levels were significantly lower in the treatment group (111.6 ± 51 mg/dL, n = 59) compared to the untreated group (124.3 ± 40.2 mg/dL, n = 238; p = 0.041). Multivariable regression analysis adjusted for age, gender, BMI, eGFR, and LLT revealed that albuminuria was a significant independent determinant of total cholesterol (β=0.315; p < 0.001) and LDL-C levels (β=0.242; p < 0.001). Male gender was associated with significantly higher LDL-C and lower HDL-C levels. Conversely, eGFR and BMI were not significant predictors of cholesterol levels. This association was also observed in the pediatric cohort (n = 44), where albuminuria was the only independent predictor of cholesterol (β=0.728; p < 0.001). Hypercholesterolemia is highly prevalent in young patients with AS and is primarily driven by the severity of albuminuria, rather than other risk factors such as obesity or eGFR decline. These findings highlight a critical gap in current guidelines, support the implementation of early lipid screening and suggest that risk-adapted management may be necessary to prevent long-term cardiovascular complications.
2026-07-02 | Patient-derived human induced pluripotent stem cell podocytes uncover endoplasmic reticulum and oxidative stress-mediated dysfunction in X-linked Alport syndrome.
X-linked Alport syndrome (XLAS) is an inherited nephropathy caused by pathogenic COL4A5 variants that lead to podocyte dysfunction and progressive kidney failure. However, the involvement of endoplasmic reticulum (ER) stress and oxidative stress in the development of XLAS remains insufficiently understood. This study aims to elucidate the contribution of ER and oxidative stress to podocyte injury in XLAS employing a patient-derived human induced pluripotent stem cell (hiPSC)-based podocyte model. Induced pluripotent stem cells were derived from XLAS patient blood cells and differentiated into podocytes (XLAS podocyte). Expression of pluripotency, lineage-specific, and podocyte markers was confirmed. ER stress, oxidative stress, and mitochondrial morphology were assessed through molecular characterization, imaging, and functional assays, comparing XLAS podocytes to wild-type (WT) hiPSC-derived podocytes. XLAS patient-derived hiPSCs maintained typical pluripotency markers, exhibited normal karyotypes, and allowed for successful tri-lineage differentiation. Relative to WT podocytes, XLAS podocytes had diminished expression of NPHS1, WT1, and COL4A5, while COL4A1 was increased. ER stress marker expression was elevated, with lower levels of CANX and CALR, indicative of unfolded protein response (UPR) activation. Electron microscopy analysis demonstrated enhanced ER enlargement in XLAS podocyte, implicating ER stress in disease pathogenesis. Moreover, XLAS podocytes showed markedly raised oxidative stress markers and mitochondrial reactive oxygen species (ROS) levels, together with altered catalase protein expression. Viability assays further supported ER and oxidative stress as contributors to reduced podocyte survival in XLAS podocyte. Our findings indicate that ER stress and oxidative stress are critical drivers of podocyte dysfunction in XLAS. UPR activation, ROS accrual, and mitochondrial impairment point to important therapeutic opportunities.
2026-06-19 | Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology.
Alport syndrome (AS) is a hereditary kidney disorder characterized by progressive hematuria, proteinuria, and kidney failure, frequently accompanied by hearing loss and ocular abnormalities. Although blockade of the renin-angiotensin system (RAS) is established as the first-line therapy, additional pharmacological interventions have been explored. To formulate evidence-based recommendations tailored to the Korean healthcare setting, the Genetic Kidney Disease Study Group of the Korean Society of Nephrology conducted a systematic review evaluating four therapeutic strategies: RAS blockade, cyclosporine, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation framework. The review confirmed that early initiation of RAS blockade delays progression to kidney failure and improves long-term survival, with the greatest benefit when initiated at the stage of microscopic hematuria or microalbuminuria. In contrast, evidence supporting cyclosporine , MRAs, and SGLT2i remains limited, primarily derived from small observational studies with short follow-up and heterogeneous populations. Although cyclosporine and MRAs have demonstrated short-term reductions in proteinuria, neither has shown sustained renoprotective effects, and cyclosporine is associated with a substantial risk of nephrotoxicity. Evidence regarding SGLT2i is inconsistent, with insufficient data on long-term efficacy in AS. Accordingly, these guidelines strongly recommend early RAS blockade as the cornerstone of AS, while no recommendations are made for routine use of cyclosporine, MRAs, or SGLT2i. Well-designed clinical trials are needed to expand therapeutic options and improve long-term outcomes in AS.
2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.
The global burden of chronic and genetic kidney diseases poses a significant challenge to healthcare systems. Current therapies, including dialysis, transplantation, and supportive pharmacotherapies, cannot halt disease progression or address root causes, especially in monogenic disorders like Alport syndrome and Fabry disease. Adeno-associated virus (AAV)-based gene therapy is promising, enabling targeted correction of underlying genetic defects. However, renal delivery faces challenges, including cellular heterogeneity, anatomical barriers, and pre-existing immunity. This review evaluates advances in AAV capsid engineering to overcome these obstacles, focusing on strategies to enhance kidney-specific tropism, transduction efficiency, and immune evasion. We outline the evolution from conventional serotype selection to precision engineering via rational design, directed evolution, and in silico approaches. Artificial intelligence (AI) has emerged as a pivotal accelerator, with machine learning models and generative frameworks enabling data-efficient capsid optimization despite limited datasets. Multimodal AI, reinforcement learning, and agentic systems can refine renal targeting by balancing glomerular penetration, cell specificity, and safety. Future progress relies on scaling high-quality datasets through collaborative consortia, lab-in-the-loop validation, and explainable AI. By combining capsid engineering with renal pathophysiology insights, this roadmap paves the way for curative AAV therapies that move beyond current suboptimal treatments to correct underlying pathogenic mechanisms.
2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.
Alport syndrome (AS) is an inherited disorder of the glomerular basement membrane (GBM) resulting from pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes, which encode the α3, α4, and α5 chains of type IV collagen, the main structural component of the GBM, cochlea, and lens capsule.Defects in this collagen network lead to progressive renal insufficiency, hearing impairment, and characteristic ocular lesions such as anterior lenticonus and retinal flecks.(1).AS affects approximately 1 in 50 000 live births.The disease is classically inherited in an X-linked pattern (85%), followed by autosomal recessive (15%) and autosomal dominant (< 1%) forms.The severity and age at onset vary depending on the mutation type and zygosity, with males with truncating COL4A5 variants typically progressing faster to end-stage kidney disease (ESKD).( 2 )
2026-05-15 | Albuminuria drives hyperlipidemia in patients with Alport syndrome.
Hypercholesterolemia is a major driver of cardiovascular disease, a leading cause of premature mortality in patients with chronic kidney disease (CKD). Despite their typically young age, patients with Alport syndrome (AS), the second most prevalent genetic cause of CKD, may face a disproportionately high risk of hypercholesterolemia. This study investigates whether increased albuminuria precipitates hyperlipidemia in this population to a degree comparable with general CKD cohorts, while further delineating the risk factors underlying this development. This was a multicenter, observational, non-interventional, and retrospective study. Among 459 patients with AS, 59.3% had hypercholesterolemia and 58.5% had elevated low-density lipoprotein cholesterol (LDL-C). Despite lower eGFR and higher albuminuria, patients with lipid-lowering therapy (LLT) had significantly lower total cholesterol levels compared to the untreated patients (193.6 ± 55.2 mg/dL vs. 208.2 ± 51.0 mg/dL; p = 0.044). Similarly, LDL-C levels were significantly lower in the treatment group (111.6 ± 51 mg/dL, n = 59) compared to the untreated group (124.3 ± 40.2 mg/dL, n = 238; p = 0.041). Multivariable regression analysis adjusted for age, gender, BMI, eGFR, and LLT revealed that albuminuria was a significant independent determinant of total cholesterol (β=0.315; p < 0.001) and LDL-C levels (β=0.242; p < 0.001). Male gender was associated with significantly higher LDL-C and lower HDL-C levels. Conversely, eGFR and BMI were not significant predictors of cholesterol levels. This association was also observed in the pediatric cohort (n = 44), where albuminuria was the only independent predictor of cholesterol (β=0.728; p < 0.001). Hypercholesterolemia is highly prevalent in young patients with AS and is primarily driven by the severity of albuminuria, rather than other risk factors such as obesity or eGFR decline. These findings highlight a critical gap in current guidelines, support the implementation of early lipid screening and suggest that risk-adapted management may be necessary to prevent long-term cardiovascular complications.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
14 orphan drug designations for Alport syndrome.
14 orphan drug designations for Alport syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Exaluren sulfate | small molecules | EMA | 2026-03-25 | — | FGK Representative Service GmbH |
a human monoclonal antibody that blocks the function of semaphorin-3A | antibodies | FDA | 2025-05-07 | — | Bayer HealthCare Pharmaceuticals Inc. |
6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-alpha-Ltalofuranosyl)-paromamine sulfate | small molecules | FDA | 2024-04-10 | — | Eloxx Pharmaceuticals Inc. |
Setanaxib | small molecules | EMA | 2023-11-08 | — | Calliditas Therapeutics AB |
setanaxib | small molecules | FDA | 2023-09-26 | — | Calliditas Therapeutics AB |
Vonafexor | small molecules | FDA | 2023-08-09 | — | ENYO Pharma |
Vonafexor | small molecules | EMA | 2023-07-25 | — | ENYO Pharma |
5-(3,4-Dichloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide | small molecules | EMA | 2023-06-20 | — | Veristat Spain S.L. |
5-Arylnicotinamide ABCA1 inducer | small molecules | FDA | 2023-02-22 | — | River 3 Renal Corp. |
Ivaltinostat | small molecules | FDA | 2021-11-04 | — | CG Invites Co., Ltd. |
Bardoxolone methyl | small molecules | EMA | 2018-05-25 | — | Reata Ireland Limited |
bardoxolone methyl | small molecules | FDA | 2017-07-03 | — | Reata Pharmaceuticals, Inc. |
Lademirsen [RG-012] | oligonucleotides | EMA | 2015-03-19 | — | Sanofi B.V. |
single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21 | oligonucleotides | FDA | 2014-07-17 | — | Genzyme Corporation |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.